

CURRICULUM VITAE

Brent A. Neuschwander-Tetri, M.D.

CURRENT ADDRESSES:

Office: Division of Gastroenterology and Hepatology
Saint Louis University Health Sciences Center
3635 Vista Avenue
St. Louis, MO 63110-0250
(314) 577-8764 fax: (314) 577-8125



e-mail: tetriba@slu.edu

DATE OF BIRTH: January 23, 1956

PLACE OF BIRTH: Lompoc, CA

EDUCATION AND TRAINING:

1979 University of Oregon, B.S.
Major: General Science
Minor: Chemistry

1983 Yale University, New Haven, CT, M.D.

1983-1986 Internship and Residency, Internal Medicine, University of Wisconsin Hospital and Clinics, Madison, WI

1986-1990 Fellowship in Gastroenterology, University of California San Francisco and UCSF Liver Center Laboratory, San Francisco, CA

MEDICAL LICENSURE:

California, Missouri, Wisconsin

PROFESSIONAL APPOINTMENTS:

1990-1991 Assistant Adjunct Professor of Medicine, University of California San Francisco;
Staff Physician, San Francisco VAMC, San Francisco, CA

1991-1997 Assistant Professor of Internal Medicine, Division of Gastroenterology and
Hepatology, Saint Louis University School of Medicine, St. Louis, MO

1997-pres. Associate Professor of Internal Medicine, Division of Gastroenterology and
Hepatology, Saint Louis University School of Medicine, St. Louis, MO

SOCIETIES AND MEMBERSHIPS:

American College of Physicians
American Association for the Study of Liver Diseases
American Pancreatic Association
Midwest Gut Club
American Federation of Medical Research
Central Society for Clinical Research

HONORS, AWARDS AND CERTIFICATIONS:

1986 Diplomat, American Board of Internal Medicine
1986 American Liver Foundation Fellowship
1989 Diplomat, Subspecialty Board of Gastroenterology
1987-1990 American Philosophical Society Daland Research Fellowship

PROFESSIONAL SERVICE:

Medical Advisory Committee, American Liver Foundation Missouri Chapter, 1999-present
Practice Guidelines Committee, American Association for the Study of Liver Diseases, 2001-present
Co-organizer, AASLD Single Topic Conference ANonalcoholic steatohepatitis,@ September 2002

ADVOCACY:

Testimony for Childhood Hepatitis A Vaccination. Missouri House Committee on Public Health Policy, February 20, 2001.

ACADEMIC ACTIVITIES:

Editorial board: Clinical Gastroenterology and Hepatology
Ad hoc reviewer: Merit Review Board, Department of Veteran Affairs
Ad hoc reviewer: Journal of Clinical Investigation, Hepatology, Gastroenterology, American Journal of Gastroenterology, American Journal of Physiology, Journal of Cellular Physiology, Biochemical Pharmacology, Laboratory Investigation

TEACHING:

Course Director, Second year medical student core curriculum GI Module, 2001-present

RESEARCH SUPPORT:

NIH FIRST Award DK50178, ATranscriptional Control of Inflammation in Pancreatitis,@ 1995-2000, direct costs \$350,000.

Principal Investigator, AA Pilot Study of Rosiglitazone for Nonalcoholic Steatohepatitis,@ SmithKline Beecham, 1999-2002, direct costs \$114,643.

Coinvestigator, AHepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C),@ NIDDK, Adrian DiBisceglie, principal investigator, 1999-2004.

Principal Investigator, AHyperinsulinemia and the Pathogenesis of NASH,@ NIDDK, 2002-2007, direct costs \$1,406,760.

PUBLICATIONS:

1. Harris TD, **Neuschwander BA** and Boekelheide V. A synthesis of trans-15-n-butyl-16-methyl-dihdropyrene. Synthetic access to 1,2,3-trisubstituted benzene derivatives via direct alkylation of 1,3-bis(4',4'-dimethyl-2'oxazoliny)benzene. *Journal of Organic Chemistry* 43:727-730, 1978.
2. **Neuschwander BA** and Boekelheide V. Two syntheses of [2.2.2](1,2,3)cyclophane. *Israel Journal of Chemistry* 20:288-290, 1980.
3. **Neuschwander-Tetri BA** and Roll FJ. Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione-orthophthalaldehyde adduct. *Analytical Biochemistry* 179:236-241, 1989.
4. **Neuschwander-Tetri BA** and Roll FJ. Chemotactic activity for human PMN generated during ethanol metabolism by rat hepatocytes: role of glutathione and glutathione peroxidase. *Biochemical and Biophysical Research Communications* 167:1170-1176, 1990.
5. **Neuschwander-Tetri BA**, Ferrell LD, Sukhabote RJ and Grendell JH. Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. *Journal of Clinical Investigation* 89:109-116, 1992.
6. **Neuschwander-Tetri BA**, Barnidge M and Janney CG. Caerulein-induced pancreatic cysteine depletion: prevention does not diminish acute pancreatitis in the mouse. *Gastroenterology* 107:824-830, 1994.
7. Ho SB, Yan P-S, Dahiya R, **Neuschwander-Tetri BA**, Basbaum C and Kim YS. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. *Journal of Cellular Physiology* 160:213-226, 1994.
8. Bacon BR, Faravash MJ, Janney CG and **Neuschwander-Tetri BA**. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 107:1103-1109, 1994.
9. Sokol RJ, Twedt D, McKim JM Jr, Devereaux MW, Karrer FM, Kam I, Von Steigman G, Bacon BR, Britton RS and **Neuschwander-Tetri BA**. Oxidant injury to hepatic mitochondria in copper toxicity: evidence from Wilson's disease patients and Bedlington terriers with copper toxicosis. *Gastroenterology* 107:1788-1798, 1994.
10. Luthen RE, **Neuschwander-Tetri BA**, Niederau C, Ferrell LD and Grendell JH. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms. *International Journal of Pancreatology* 16:31-36, 1994.
11. Presti ME and **Neuschwander-Tetri BA**. Nafcillin associated hepatotoxicity: report of a case and review of the literature. *Digestive Diseases and Sciences* 41:180-184, 1996.
12. **Neuschwander-Tetri BA** and Rozin T. Diurnal variability of cysteine and glutathione content in the pancreas and liver of the mouse. *Comparative Biochemistry and Physiology* 114B:91-95, 1996.
13. **Neuschwander-Tetri BA**, Nicholson C, Wells LD and Tracy, TF Jr. Cholestatic liver injury down-regulates hepatic glutathione synthesis. *Journal of Surgical Research* 63:447-451, 1996.
14. **Neuschwander-Tetri BA**, Bellezzo JM, Britton RS, Bacon BR and Fox ES. Thiol regulation of endotoxin-induced tumor necrosis factor- α release from isolated rat Kupffer cells. *Biochemical Journal* 330:1005-1010, 1996.
15. **Neuschwander-Tetri BA**, Presti ME and Wells LD. Glutathione synthesis in the exocrine pancreas. *Pancreas* 14:342-349, 1997.
16. Maher JJ, Saito JM and **Neuschwander-Tetri BA**. Glutathione regulation in rat hepatic stellate cells: comparative studies in primary culture and in liver injury in vivo. *Biochemical Pharmacology* 53:637-641, 1997.
17. Presti ME, **Neuschwander-Tetri BA**, Vogler CA, Janney CG and Roche JK. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. *Digestive Diseases and Sciences* 42:813-816, 1997.
18. Maher JJ and **Neuschwander-Tetri BA**. Manipulation of glutathione stores in rat hepatic stellate cells does not alter collagen synthesis. *Hepatology* 26:618-623, 1997.
19. **Neuschwander-Tetri BA**, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ and Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation. *Annals of Internal Medicine*, 129:38-41, 1998.
20. Fan X, Solomon H, Poulos JE, **Neuschwander-Tetri BA**, Di Bisceglie AM. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. *American Journal of Gastroenterology*, 94:1347-1354, 1999.
21. Fan X, Xu Y, Solomon H, Ramrakhiani S, **Neuschwander-Tetri BA**, Di Bisceglie AM. Is hepatitis G/GB virus hepatotropic? Detection of hepatitis G/GB virus-C viral RNA in liver and serum. *Journal of Medical Virology*,

- 58:160-164, 1999.
22. Brunt EM, Janney CG, Di Bisceglie AM, **Neuschwander-Tetri BA**, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. *American Journal of Gastroenterology*, 94:2467-2474, 1999.
 23. **Neuschwander-Tetri BA**, Burton FR, Presti ME, Britton RS, Janney CG, Garvin PR, Brunt EM, Galvin NJ, Poulos JE. Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. *Digestive Diseases and Sciences*, 45:665-674, 2000.
 24. **Neuschwander-Tetri BA**, Bridle KR, Wells LD, Marcu M, Ramm GA. Repetitive acute pancreatic injury in the mouse induces procollagen $\alpha_1(I)$ expression colocalized to pancreatic stellate cells. *Laboratory Investigation*, 80:143-150, 2000.
 25. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson, MC, **Neuschwander-Tetri BA**, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. *Nature*, 406:435-439, 2000.
 26. Jawaid Q, Presti ME, **Neuschwander-Tetri BA**, Burton FR. Acute pancreatitis after a single dose exposure to propofol: a case report and review of literature. *Digestive Diseases and Sciences*, 47:614-618, 2002.
 27. Brunt EM, Ramrahkiani S, Cordes BG, **Neuschwander-Tetri BA**, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. *Modern Pathology* 16:49-56, 2003.
 28. **Neuschwander-Tetri BA**, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR- γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. *Journal of Hepatology*, 38:434-440, 2003.
 29. **Neuschwander-Tetri BA** and Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology*, 37:in press, 2003.
 30. Poulos JE, Weber JE, **Neuschwander-Tetri BA**, Wells LD, Britton RS, Bacon BR, Baldassare JJ. Activation of extracellular signal-regulated kinase and AP-1 dependent gene expression by RGD in hepatic stellate cells is suppressed by N-acetylcysteine. Submitted.
 31. **Neuschwander-Tetri BA**, Wells LD, Ramrahkiani S. Pancreatic nuclear transcription factor-kappa B activation in experimental acute pancreatitis. Submitted.
 32. Scalzo A, Blume C, **Neuschwander-Tetri BA**, Weber J, Madhock M, Thompson M. *Amanita bisporigera*: dose related toxicity from intentional abuse/mistaken identity. Submitted.
 33. Gundala S, Wells LD, Milliano MT, Luxon BA, **Neuschwander-Tetri BA**. Uptake of the mushroom toxin α -amanitin is mediated by the hepatocellular bile acid transporter Ntcp. Submitted.

BOOK CHAPTERS, EDITORIALS, REVIEWS, MISCELLANEOUS:

34. **Neuschwander-Tetri BA** and Bacon BR. AGA undergraduate teaching project unit No. 26. Portal hypertension: varices and variceal hemorrhage (book review). *American Journal of Gastroenterology* 88:1303, 1993.
35. **Neuschwander-Tetri BA**. Organ interactions in the hepatorenal syndrome. In: *New Horizons: The Science and Practice of Critical Care Medicine*, Matuschak GM, ed. Society of Critical Care Medicine, Anaheim, Vol. 2, pp 527-544, 1994.
36. **Neuschwander-Tetri BA**. Common blood tests for liver disease. *Postgraduate Medicine* 98:49-63, 1995.
37. **Neuschwander-Tetri BA**. The liver in systemic disease. In: *Current Therapy in Gastroenterology*, Grendell JH, McQuaid KR, and Friedman SL, eds. Appleton and Lange, Stamford CT, pp 585-597, 1996.
38. Riegel RT and **Neuschwander-Tetri BA**. Liver function tests. *Hospital Physician*, 32:13-19, 1996.
39. **Neuschwander-Tetri BA** and Bacon BR. Nonalcoholic steatohepatitis. In: *Medical Clinics of North America: Management of Chronic Liver Disease*, Martin P, and Friedman LS, eds. WB Saunders, Philadelphia, PA, Vol. 80, pp 1147-1166, 1996.
40. **Neuschwander-Tetri BA** and Bacon BR. Viral hepatitis. In: *Current Diagnosis 9*, Conn RB, Borer WZ, and Snyder JW, eds. WB Saunders, Philadelphia PA, pp 644-650, 1997.
41. **Neuschwander-Tetri BA** and Bacon BR. Fatty liver and nonalcoholic steatohepatitis. In: *Handbook of Liver*

- Disease*, Friedman LS and Keefe EB, eds. Churchill Livingstone, Edinburgh, UK, pp 95-102, 1998.
42. **Neuschwander-Tetri BA**. Fatty liver and nonalcoholic steatohepatitis. In: *Clinics in Liver Disease: Metabolic Liver Disease*, Rosen HR and Martin P, eds. WB Saunders, Philadelphia, PA, Vol. 2, pp 149-173, 1998.
 43. **Neuschwander-Tetri BA**. They're everywhere: stellate cells in the pancreas (editorial). *Hepatology*, 29:294-295, 1999.
 44. **Neuschwander-Tetri BA**, Isley WL, Oki JC. Troglitazone-associated hepatic failure (letter). *Annals of Internal Medicine*, 130:330, 1999.
 45. **Tetri, BA**. Update on NASH. In: *Clinical Advances in Gastroenterology Audiocassette Series*, Vol. 11 (3), Sharma P, ed. American College of Gastroenterology and Oakstone Medical Publishing, Birmingham, AL, March, 2000.
 46. **Neuschwander-Tetri BA**. Fatty liver, nonalcoholic steatohepatitis. In: *Liver Disease: Diagnosis and Management*, Bacon BR and Di Bisceglie AM, eds. WB Saunders, Philadelphia, pp 127-139, 2000.
 47. **Neuschwander-Tetri BA**. Nonalcoholic steatohepatitis: an evolving diagnosis. *Canadian Journal of Gastroenterology*, 14:321-326, 2000.
 48. **Neuschwander-Tetri BA**. Liver Tests. In: *Clinical Laboratory Pearls*, Jones SL, ed. Lippincott Williams & Wilkins, Philadelphia, pp 432-439, 2001.
 49. **Neuschwander-Tetri BA**. The pathogenesis of nonalcoholic steatohepatitis. *Progress in Hepato-Pharmacology*, 6:29-38, 2001.
 50. **Neuschwander-Tetri BA**. Fatty liver and nonalcoholic steatohepatitis. *Clinical Cornerstone*, 3:47-57, 2001.
 51. **Neuschwander-Tetri BA**. Betaine: an old therapy for a new scourge (editorial). *American Journal of Gastroenterology*, 96:2534-2536, 2001.
 52. **Neuschwander-Tetri BA**. A resistance movement in NASH (editorial). *American Journal of Gastroenterology*, 96:2813-2814, 2001.
 53. **Neuschwander-Tetri BA**. Evolving pathophysiological concepts in nonalcoholic steatohepatitis. *Current Gastroenterology Reports*, 4:31-36, 2002.
 54. Brunt EM, Ramrahkiani S, Cordes BG, **Neuschwander-Tetri BA**, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. *Modern Pathology* 16:49-56, 2003.
 55. Habib A, **Neuschwander-Tetri BA**. The liver in systemic disease. In: *Current Therapy in Gastroenterology, Second Edition*, Grendell JH, Friedman SL, and McQuaid KR, eds. Appleton and Lange, Stamford CT, pp 680-695, 2003.
 56. **Neuschwander-Tetri BA** and Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 37:1202-1219, 2003.
 57. Habib A, Matuschak GM, **Neuschwander-Tetri BA**. Recent advances in the management of liver disorders. *American Journal of Respiratory and Critical Care Medicine*, in press, 2003.
 58. **Neuschwander-Tetri BA**. Bacterial, parasitic, fungal, and granulomatous liver diseases. In: *Cecil Textbook of Medicine, 22nd Edition*, Goldman L and Ausiello D, eds. WB Saunders, Orlando, FL, in press, 2003.
 59. **Neuschwander-Tetri BA** and Bacon BR. Fatty liver and nonalcoholic steatohepatitis. In: *Handbook of Liver Disease, 2nd Edition*, Friedman LS and Keefe EB, eds. Churchill Livingstone, Edinburgh, UK, in press, 2003.

INVITED TALKS:

60. Nonalcoholic Steatohepatitis: An Update. American College of Gastroenterology Annual Postgraduate Gastroenterology Course, Boston, October 11, 1998.
61. Diagnosis and Treatment of Hepatitis C. Marion VA Medical Center, June 3, 1999.
62. Recent Advances in Nonalcoholic Steatohepatitis. Minneapolis VA Medical Center Grand Rounds, March 10, 2000.
63. The Pathogenesis of Nonalcoholic Steatohepatitis. Annual Congress of the Slovak Society of Hepatology, Bratislava, Slovak Republic, May 25, 2001.
64. Hepatitis C and Nonalcoholic Fatty Liver Disease. AASLD Single Topic Conference, A Comorbid Conditions Associated with Hepatitis C, @ Chicago, April 27, 2002.
65. Nonalcoholic Steatohepatitis: Lessons from Bariatric Surgery. NIH Workshop on Bariatric Surgery and Obesity, Bethesda, MD, May 9, 2002.

66. Pathophysiology and Treatment of NASH. AASLD Clinical Symposium at Digestive Disease Week, San Francisco, May 20, 2002.
67. Insulin Sensitizing Agents and NASH. AASLD Single Topic Conference, ANonalcoholic Steatohepatitis, @ Atlanta, GA, September 22, 2002.